Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.85 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.81 |
| ▸ | CNR2 | P34972 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.80 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | PTGES | O14684 | 1/20 | 0.79 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | ALB | P02768 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.79 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxametacin SCHEMBL24552 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2AKR1C3CNR2MAPT | |
| SCHEMBL14405006 | 0.92 | PTGS2 (1.00) | PTGS1PTGS2AKR1C3CNR2MAPT | |
| SCHEMBL20259394 | 0.91 | PTGS2 (0.83) | PTGS1PTGS2AKR1C3CNR2MAPT | |
| SCHEMBL9657228 | 0.91 | PTGS1 (0.85) | PTGS1PTGS2AKR1C3CNR2MAPT | |
| SCHEMBL14398315 | 0.90 | PTGS1 (0.82) | PTGS1PTGS2AKR1C3CNR2MAPT | |
| SCHEMBL5107049 | 0.90 | PTGS2 (0.82) | PTGS1PTGS2AKR1C3CNR2MAPT | |
| SCHEMBL5112013 | 0.90 | PTGS2 (0.84) | PTGS1PTGS2 | |
| SCHEMBL30426824 | 0.89 | PTGS2 (1.00) | PTGS1PTGS2AKR1C3CNR2MAPT | |
| SCHEMBL14086813 | 0.89 | PTGS2 (1.00) | PTGS1PTGS2AKR1C3CNR2MAPT | |
| SCHEMBL17378074 | 0.89 | PTGS2 (0.80) | PTGS1PTGS2AKR1C3CNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4628080-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DRUG-RELATED PEPTIC ULCER COMPRISING ZASTAPRAZAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Jeil Pharmaceutical Co., Ltd. (KR) | 2025-10-08 | — | — | EP | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-3508501-B1 | USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS | H LUNDBECK AS (DK) | 2024-11-06 | — | — | EP | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| CN-118647367-A | Novel injectable combination formulations | 南爱克萨股份公司 | 2024-09-13 | — | — | CN | claimed |
| WO-2024117797-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DRUG-RELATED PEPTIC ULCER COMPRISING ZASTAPRAZAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 제일약품 주식회사 | 2024-06-06 | — | — | WO | claimed |
| WO-2024105529-A1 | CHEMICAL DISBUDDING OF LIVESTOCK | MASSEY UNIVERSITY (NZ) | 2024-05-23 | — | — | WO | claimed |
| EP-4340884-A1 | TREATMENT OF INFECTIONS IN AND AROUND THE EYE | University of Miami (US) | 2024-03-27 | — | — | EP | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| WO-2022245950-A1 | TREATMENT OF INFECTIONS IN AND AROUND THE EYE | UNIVERSITY OF MIAMI (US) | 2022-11-24 | — | — | WO | claimed |
| US-20220117921-A1 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PAIN | IMUNEKS FARMA ILAC SANAYI VE TICARET A.S. (TR) | 2022-04-21 | — | — | US | claimed |
| US-20260125335-A1 | SYNTHETIC CANNABINOID ANALOGS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING BACTERIAL INFECTIONS AND OTHER DISORDERS | MIRALOGX LLC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-3938345-B1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260117177-A1 | T-CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | DARTMOUTH COLLEGE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-3952882-A1 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE TREATMENT OF PAIN | Intrinsic Medicine, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20220040309-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220041552-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220040102-A1 | Solid Solution Compositions and Use in Chronic Inflammation | INFIRST HEALTHCARE LIMITED (GB) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041552-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPA1 | PTGS1 478/4885PTGS2 465/4885AKR1C3 2430/4885 |
| US-20260117177-A1 | T-CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS | ICOS, CD4, CD2 | PTGS1 4491/4885PTGS2 4390/4885AKR1C3 4264/4885 |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | OPRL1, TRPV1, SCN2B | PTGS1 642/4885PTGS2 689/4885AKR1C3 506/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | PTGS1 1329/4885PTGS2 730/4885AKR1C3 1800/4885 |
| US-20260125335-A1 | SYNTHETIC CANNABINOID ANALOGS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING BACTERIAL INFECTIONS AND OTHER DISORDERS | CNR1, CNR2, FAAH | PTGS1 1674/4885PTGS2 2183/4885AKR1C3 895/4885 |
| US-20220040309-A1 | COMPOSITIONS WITH PERMEATION ENHANCERS FOR DRUG DELIVERY | ABCB11, MMP1, SLC47A1 | PTGS1 13/4885PTGS2 63/4885AKR1C3 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.